Gilead Sciences Inc.

13 juil. 2026, 17:26 UTC

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

10 juil. 2026, 20:01 UTC

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

9 juil. 2026, 19:36 UTC

Gilead Sciences Inc's shares are lower despite regulatory achievements for Trodelvy and advancements in its HIV pipeline, reflecting broader market volatility.

8 juil. 2026, 23:51 UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

7 juil. 2026, 23:02 UTC

Gilead Sciences Inc. shares are lower in after-market hours, reflecting broader market declines amid rising geopolitical tensions and a widening U.S. trade deficit.

6 juil. 2026, 20:02 UTC

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2 juil. 2026, 22:56 UTC

Gilead Sciences shares traded lower in after-market hours, with no specific news identified. Broader market mixed amid weaker U.S. jobless data.

1 juil. 2026, 19:14 UTC

Gilead Sciences Inc. shares are lower today, reflecting routine performance within their one-month trading range despite stability around the midpoint.

30 juin 2026, 20:07 UTC

A social media post suggests bullish sentiment around Gilead Sciences, as a fund buys March call options. Shares are trading roughly flat in the session.

29 juin 2026, 23:06 UTC

Gilead Sciences Inc. shares are trading lower in after-market hours. Investor focus remains on upcoming U.S.-Iran talks that may impact market sentiment.

26 juin 2026, 22:11 UTC

Gilead Sciences Inc shares are lower in after-market hours, driven by notable declines in the Biotechnology sub-sector. No specific company news was identified.

25 juin 2026, 23:56 UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.

24 juin 2026, 23:36 UTC

Gilead Sciences' Trodelvy receives FDA approval for first-line treatment of triple-negative breast cancer, boosting shares in after-market hours.

23 juin 2026, 23:56 UTC

European Commission approves Gilead's Trodelvy for triple-negative breast cancer, boosting shares higher in after-market hours amid notable intraday fluctuations.

22 juin 2026, 23:02 UTC

Gilead Sciences Inc shares are lower in after-market hours, reversing earlier gains and settling near the lower end of their one-month trading range.

18 juin 2026, 23:06 UTC

Gilead Sciences shares are lower in after-market trading, reflecting a decline since Thursday's close and nearing the lower end of their one-month range.

17 juin 2026, 23:16 UTC

Gilead Sciences Inc. shares are lower in after-market hours, with notable volatility earlier in the session. No specific news was identified to explain the decline.

16 juin 2026, 23:36 UTC

Gilead Sciences Inc. shares gained slightly in after-market trading, fluctuating within a narrow range amid limited volatility and no specific company news.

15 juin 2026, 21:11 UTC

Gilead Sciences' supplemental New Drug Application for Yeztugo accepted by the FDA. Shares are lower in after-market trading despite the regulatory milestone.

12 juin 2026, 23:01 UTC

Gilead Sciences Inc. shares are higher in after-market trading, gaining slightly since Friday's close despite mixed broader market sentiment.

11 juin 2026, 23:02 UTC

Gilead Sciences reported positive results from two Phase 3 trials for an HIV treatment. Shares are higher in after-market hours following a session pullback.

10 juin 2026, 23:11 UTC

Gilead Sciences shares rose in after-market trading, driven by a strong Biotechnology sub-sector trend. The stock remains below its 20-day moving average.

9 juin 2026, 23:21 UTC

Gilead Sciences Inc shares are higher in after-market trading, rebounding from earlier losses despite remaining below the 20-day moving average.

8 juin 2026, 23:26 UTC

Gilead Sciences Inc. shares declined in after-market trading following the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for Trodelvy and Keytruda.

5 juin 2026, 23:46 UTC

Gilead Sciences shares declined in after-market trading amid broader market pressures from strong U.S. job growth raising interest rate concerns.

4 juin 2026, 19:46 UTC

Gilead Sciences is gaining amid social media discussions on its strategic positioning and attention at Goldman Sachs' healthcare conference.

3 juin 2026, 23:01 UTC

Gilead Sciences Inc. is higher in after-market trading, driven by gains in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

2 juin 2026, 23:02 UTC

Gilead Sciences reported positive Phase 3 study results for Livdelzi® in treating primary biliary cholangitis. Shares are trading higher in after-market hours.

1 juin 2026, 20:03 UTC

Gilead Sciences Inc. shares are lower amid broader market concerns, despite plans to present over 25 abstracts at the ASCO Annual Meeting and EHA Congress.

29 mai 2026, 20:02 UTC

Gilead Sciences is declining during Friday's session, despite the World Health Organization considering it for Ebola therapies. Shares rebounded earlier but fell back.